Daewoong Pharmaceutical Co., Ltd.

59 articles about Daewoong Pharmaceutical Co., Ltd.

• Daewoong Pharmaceutical Announces 2023 Financial Results

  2/6/2024

  Daewoong Pharmaceutical, a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.

• Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

  1/29/2024

  Daewoong Pharmaceutical's Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis (IPF), a rare and debilitating disease.

• HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum

  12/20/2023

  HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum.

• Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results

  11/1/2023

  Daewoong Pharmaceutical is pleased to announce its financial results for the third quarter of 2023.

• Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

  10/19/2023

  Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions.

• HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192

  10/12/2023

  HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals.

• Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

  5/25/2023

  Daewoong Pharmaceutical announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

• Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

  5/19/2023

  Daewoong Pharmaceutical (CEO Lee Chang -jae and Jeon Sengho) announced on the 19th that that they set up a booth at the Digestive Disease Week® 2023 (DDW 2023) held in Chicago, USA and revealed new clinical data through two poster sessions demonstrating the efficacy and safety of Fexuclue® (active ingredient name: Fexuprazan) on patients with gastroesophageal reflux disease (GERD).

• Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

  4/28/2023

  Daewoong Pharmaceutical announced that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.

• Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue

  2/20/2023

  Daewoong Pharmaceutical announced its 2022 annual report. On a standalone basis, sales increased from the previous year by 10.1% to KRW 1.16 trillion with business profits increased by 11.0% to KRW 106 billion and net profits increased by 123.9% to KRW 80.1 billion, respectively.

• Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial

  2/6/2023

  The world's first-in-class candidate substance against idiopathic pulmonary fibrosis, 'Bersiposocin', which is under development Daewoong Pharmaceutical, has entered its Phase II clinical administration.

• Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

  1/31/2023

  Sonoma Pharmaceuticals, Inc. today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products.

• Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea

  1/26/2023

  Daewoong Pharmaceutical's Fexuclue is attracting attention as a game changer in the global gastroesophageal reflux disease treatment market as it applied for approval in 11 countries across the world within one year after approval in Korea.

• Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

  1/4/2023

  Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.

• Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

  12/6/2022

  Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae), a global healthcare company, announced on 5th that its "Envlo 0.3mg", a new sodium-glucose cotransporters 2 inhibitor (SGLT2) developed to treat type 2 diabetes mellitus obtained a product license from the Ministry of Food and Drug Safety on November 30.

• Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

  11/15/2022

  Daewoong Pharmaceutical Co., Ltd. (CEO Jeon Sengho, Lee Changjae) announced the third-quarter financial results.

• Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

  11/14/2022

  Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd, a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients' lives.

• 

  FDA Weekly Review: Daewoong, Novavax, Preceptis and More

  8/19/2022

  The FDA is busy accepting drug applications, granting specialty designations and approving drugs for market. Here's a look at this week's FDA activity.

• Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases

  8/15/2022

  Daewoong Pharmaceutical is a publicly traded South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals globally today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of DWP213388, a new drug candidate being developed for autoimmune diseases.

• Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever

  7/28/2022

  Daewoong Pharmaceutical Co., Ltd. presented its management performance for the second quarter of 2022.